As the global multi-billion dollar cannabinoid and cannabis markets have officially exploded and understanding of the scientific basis supporting the use of these products remains low, Havas Health & You is stepping into the knowledge gap. The network has introduced Havas ECS, a specialized strategic communications advisory and education company focused on the importance and value of foundational scientific knowledge on the endocannabinoid system, which Havas executives hope will better guide and better inform decisions on cannabinoid use.
According to Havas Health & You management, the new unit Havas ECS is serving the use-specific needs of pharmaceutical, health, wellness and brand communities, powered by deep subject matter expertise, and a network of medical advisors skilled in the application of cannabinoid medicine.
“There are still massive gaps in the scientific understanding across the medical, public health, wellness, regulatory, patient advocacy and brand communities,” HH&Y executives say. “In fact, only 13 percent of medical schools offer any instructional material on the human endocannabinoid system (ECS), an essential biological system only discovered in the mid-1990s that regulates many aspects of human health and well-being.”
According to Havas management, the surge in cannabis self-care, and overall lack of training on the endocannabinoid system, can lead to missed opportunities, communication misunderstandings and mistrust. “These potential challenges exist in virtually every category of business, with immense pressure on healthcare providers, health and wellness leaders, insurers and the broader business community to get an understanding of this topic, and do so quickly,” HH&Y executives say.
Leading the new multi-office venture is Rob Dhoble, a proven healthcare communications executive, with a successful career spanning medical advertising, brand management, pharmaceutical marketing, and more recently, as an entrepreneur supporting the digital health needs of industry.
“Cannabinoid and cannabis use, for wellness, self-care, and healthcare, has reached new levels of relevance, and will continue to grow as new products, including foods, beverages, prescription medicines, and non-prescription remedies are introduced,” Dhoble says. “A new cannabinoid reality has arrived, now with a major network validating the space, helping clients seize marketplace opportunities, assess customer insights, and even plan for potential threats. Havas ECS addresses the urgent need for a communications advisory and training company that integrates foundational endocannabinoid science with the relevant real-world learnings of scientists and medical practitioners.”
According to management, Dhoble and his team will serve to advance the understanding of cannabinoid health and wellness, with science-based education and communication programs that frame and elevate the cannabinoid conversation, and increase the understanding of cannabinoid treatments and ECS-related medical conditions. The company will be active immediately, and plans to host its first educational conference this fall.